Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Echelon Confirms $3.75 Target

<< Previous

Bullboard Posts

Next >>

Post by steadfaston Jul 12, 2022 3:09pm

456 Views

Post# 34818821

Echelon Confirms $3.75 Target

Echelon issued a Research Note yesterday, mainting $3.75 Target advising Via-Cyte
UNLIKE , SVA, has largely demonstrated poor Clincial results to-date.
$1.12 is a bargain. Expect Evotec will honor their deal @ $2.50 August 31st, 2022.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario